Journals / Çocuk Dergisi / 2013 / Cilt: 13 - Sayı: 1

Invasive Meningococcal Disease and Vaccines

İnvaziv Meningokok Hastalığı ve Aşıları

Pages
1–5
Publication Date
2013-01-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The preferred vaccine for people ages 2-55 years is Meningococcal conjugate vaccine MCV4

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Meningococcal diseases continue to have a major public health impact in many countries.
📊
Key Findings & Data:Fatality rate of invasive meningococcal disease IMD in pediatric patients is 10 %.
💡
Conclusion & Impact:The preferred vaccine for people ages 2-55 years is Meningococcal conjugate vaccine MCV4
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Meningokok aşıları · meningokok infeksiyonu · Meningococcal infections

Abstract

Meningococcal diseases continue to have a major public health impact in many countries. Fatality rate of invasive meningococcal disease IMD in pediatric patients is 10 %. At least 75 % of cases of are caused byserogroups A, C, Y, and W-135; thus, IMD potentially is preventable by immu- nization. Plain polysaccharides vaccines for Neisseria meningit have been in use for approximately 20 years, both to prevent invasive disease in high-risk population and to control disease outbreaks. The preferred vaccine for people ages 2-55 years is Meningococcal conjugate vaccine MCV4

Özet

Meningokok infeksiyonları bütün dünyada önemli sağlık sorunları arasında yer almaya devam etmektedir. İnvaziv Meningokok hastalığı çocukluk çağında % 10 oranında ölümcül olabilmektedir. Vakaların % 75’inden serogrup A, C, Y ve W135 sorumludur. İMH aşılama ile önlenebilir bir hastalıktır. İnfeksiyonların önlenmesi için uzun yıllardan beri iki yaşından itibaren uygulanan polisakkarid aşılar risk gruplarında ve salgın kontrolünde kullanılmaktadır. İki-55 yaş arasında tercih edilen aşı, meningokok konjuge aşıdır MCV4

🔖

Cite This Article

TÖRÜN, S. H., SALMAN, N. (2013). Invasive Meningococcal Disease and Vaccines. Çocuk Dergisi, Cilt: 13 - Sayı: 1, 1–5. https://ajindex.com/articles/246819

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Centers for Disease Prevention and Control. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-7):1-10
  2. Bilukha OO, Rosenstein N. Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2005;54(RR-7):1-21. PMid:15917737 3. Anderson MS, Glode MP, Smith AL. Meningococcal disease, “Feigin RP, Cherr JD, Demmler GJ, Kaplan SL (eds): Texbook of Pediatric Infectious Diseases 5. baskı” kitabında s.1265-1280, Saunders, Philadelphia 2004
  3. Boulton RB, Alder SC, Mottice S, Catinella AP, Byington CL. Invasive meningococcal disease, Utah, 1995-2005, Emer Infect Dis 2007;13(8)
  4. Brouwer MC, Read RC, Van de Beek D. Host genetics and out come in meningococcal disease: a systematic review and meta-analysis, Lancet Infect Dis 2010;10:262-74.
  5. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose range study assessing immunogenity and safety of one dose of a new candidate meningococcal serogroups A C, W-135, Y, tctanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of the life and in young children Vaccine 2010;28-744
  6. Ceyhan M, Yıldırım İ, Balmer P, et al. A Prospective study of etiology of childhold acute bacterial meningitis, Turkey, Emer Infect Dis 2008;14:1089-96. http://dx.doi.org/10.3201/eid1407.070938 PMid:18598630 PMCid:2600347 8. Doğancı L, Baysallar M, Saraçlı MA, Hasçelik G, Pahsa A. Neisseria meningitidis W135 Turkey, Emerg Infect Dis 2004;10-936
  7. Badur S, Bakır M. Aşı kitabı. Akademi Yayınevi, Meningokok aşıları, 245-53
  8. Stephens DS, Greanwood B, Brandtzaeg P. Epidemic meningitidis, meningococcaemia and Neisseria meningitidis, Lancet 2007;369:2196.
  9. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010;9:285-98. http://dx.doi.org/10.1586/erv.10.3 PMid:20218857 12. Goria MC, Paiva MV, Salqueiro VC et al. Antimicrobial susceptibility of Neisseria meningitidis strains isolated from meningitis cases in Brazil from 2006 to 2008, Enterm Infect Microbiol Clin 2011;29:85-9. http://dx.doi.org/10.1016/j.eimc.2010.07.016 PMid:21345528 13. Centers for Disease Control and Prevention. General recommendations on immunization. Recommendations of the Advisory